How long you can take Opdivo (nivolumab) depends on the type of cancer being treated and whether the goal is to prevent recurrence or control advanced disease. In adjuvant (preventive) settings, treatment is capped at 1 year. In metastatic or advanced cancer, many indications allow treatment for up to 2 years, while others have no fixed time limit and continue as long as the drug is working.
Treatment Duration by Cancer Type
Opdivo’s approved treatment length varies significantly across its many indications. The three main patterns are: a fixed cap of about 1 year, a cap of about 2 years, or no predefined limit at all.
For advanced or metastatic cancers with a 2-year maximum, the list includes kidney cancer (when combined with cabozantinib), metastatic lung cancer (when combined with ipilimumab), advanced urothelial carcinoma, esophageal squamous cell carcinoma, gastric and gastroesophageal junction cancers, hepatocellular carcinoma, and malignant pleural mesothelioma. In all these cases, Opdivo continues until the cancer progresses, side effects become intolerable, or the 2-year mark is reached, whichever comes first.
For some cancers, there is no preset stopping point. Opdivo as a single agent for metastatic melanoma or metastatic lung cancer, for example, is given “until disease progression or unacceptable toxicity.” That means some patients stay on it for years if their cancer remains stable and they tolerate it well.
Adjuvant Treatment Is Shorter
When Opdivo is used after surgery to reduce the risk of cancer coming back, the maximum duration is 1 year. This applies to adjuvant treatment of melanoma, urothelial carcinoma, and resected esophageal or gastroesophageal junction cancer. For resectable lung cancer, the adjuvant phase after surgery allows up to 13 cycles, which works out to roughly 1 year as well.
In the neoadjuvant setting, where Opdivo is given before surgery to shrink a tumor, courses are even shorter. For resectable lung cancer, that means 3 to 4 cycles of Opdivo combined with chemotherapy before the operation takes place.
What Happens at the 2-Year Mark
The 2-year cap comes from how clinical trials were originally designed. Researchers set 24 months as a treatment window, and regulators carried those limits into the approved labeling. The key question patients and oncologists face is whether stopping at 2 years is safe if the cancer hasn’t progressed.
A real-world study tracking 173 lung cancer patients on immunotherapy (the I-STOP study) offers some answers. Among patients who stopped treatment at 24 months, median progression-free survival was about 36 months, meaning many stayed cancer-free for a full year or more after their last infusion. Overall survival was statistically no different between patients who stopped at 2 years and those who continued beyond it. And for patients whose cancer did eventually return, restarting immunotherapy achieved a response rate of 62.5%, with serious immune-related side effects occurring in only 3.5% of those retreated.
These results suggest that stopping at 2 years does not appear to shorten your life, even if the cancer returns somewhat sooner. The option to restart treatment and still get a strong response provides a meaningful safety net.
What Can End Treatment Early
Opdivo works by releasing the brakes on your immune system, which means the immune system can sometimes attack healthy tissue. These immune-related side effects are the most common reason treatment ends before the planned duration.
Severe lung inflammation, serious liver damage, or inflammation of the heart muscle all require permanent discontinuation. Severe colitis (intestinal inflammation) also leads to stopping treatment, particularly when Opdivo is used in combination with ipilimumab. Confirmed severe skin reactions like Stevens-Johnson syndrome or life-threatening infusion reactions also mean Opdivo is stopped for good.
For milder immune-related side effects, treatment is typically paused rather than permanently stopped. If symptoms resolve to a mild level within 12 weeks and steroid doses can be tapered down, Opdivo can usually be restarted. If that resolution doesn’t happen within the 12-week window, the drug is permanently discontinued.
Combination Therapy Changes the Timeline
When Opdivo is paired with ipilimumab for melanoma, the combination phase lasts only 4 doses. After that, you switch to Opdivo alone and continue until the cancer progresses or side effects become unmanageable. The combination phase is kept short because the two drugs together carry a higher risk of immune-related reactions.
For kidney cancer treated with the ipilimumab combination, the pattern is similar: 4 combination doses, then Opdivo alone with no fixed time limit. But when Opdivo is combined with cabozantinib for kidney cancer, the 2-year cap applies to the Opdivo portion.
In metastatic lung cancer, the Opdivo and ipilimumab combination (with or without a short course of chemotherapy) carries a 2-year maximum for patients whose disease hasn’t progressed.
Dosing Schedule Options
Opdivo can be given every 2 weeks or every 4 weeks, depending on the dose your oncologist selects. The every-4-week schedule means fewer clinic visits over the course of treatment, which can make a meaningful difference over months or years of therapy. Both schedules deliver the same drug exposure over time, so the choice of interval doesn’t change how long you stay on treatment or how well it works. It simply affects how often you need to come in for an infusion.
Restarting Opdivo After Stopping
If your cancer returns after completing or stopping Opdivo, restarting the same drug is a real possibility. The decision depends on why you stopped in the first place. Patients who stopped because of a serious immune-related side effect can sometimes be rechallenged with the same drug after the reaction has fully or nearly resolved, though this requires careful discussion among your medical team.
Interestingly, patients who had not yet responded to immunotherapy before their initial side effect appeared actually benefited most from retreatment, with improved progression-free and overall survival compared to staying off the drug. Patients who had already achieved a strong response before stopping showed similar outcomes whether or not they restarted, suggesting they may not need retreatment right away.